acellular pertussis

Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate, adjuvanted with CpG 1018. The Phase 1 trial will...